Patient information.

<p>Bla: Blastomere; PB: polar body; TE: trophectoderm cells; aCGH: Microarray-CGH; Met-CGH: Metaphase CGH. Note: Some patients underwent more than one cycle of PGD and may have had analysis conducted at different stages in subsequent cycles.</p

Corrected number of errors in the patient-specific control groups.

*<p>Chromosomes involved in the matching patient's rearrangement were excluded from the assessed chromosomes.</p>**<p>Abnormalities affecting chromosomes involved in the matching patient's rearrangement were excluded.</p>***<p>Expected number in the control group if it consisted of the same number of samples as provided by the matched patient.</p

Malsegregation events detected in non-rearranged chromosomes in patient and control samples.

<p>Malsegregation events detected in non-rearranged chromosomes in patient and control samples.</p

Number of embryos from each cycle and the number of chromosomes assessed along with abnormalities detected.

<p>Rec: reciprocal translocation; Rob: Robertsonian translocation; Inv: Inversion; Bla: Blastomere; PB: polar body; TE: trophectoderm cells.</p>*<p>Chromosomes involved in the rearrangement were not assessed;</p>**<p>Abnormalities affecting chromosomes involved in the rearrangement were excluded. Case 12 was the only one in which two rearrangements were present. This case was excluded from the statistical analysis.</p

Microarray-CGH analysis of an embryo from a Robertsonian translocation carrier.

<p>Cytogenetic analysis of a cleavage stage embryo from a Robertsonian translocation carrier- 46,XY,t(13;15)(q21.3;q11.2). Microarray-CGH revealed monosomy 13, presumably resulting from a meiotic error due to problems processing the rearranged chromosomes. An additional aneuploidy unrelated to the Robertsonian translocation (monosomy for chromosome 1) was also detected. The two monosomies are indicated by the altered ratio of fluorescence related to the test (embryo) and reference (46,XY) DNA samples. All of the probes corresponding to chromosomes 1 and 13 have test/reference ratios less than 0.3.</p

Data concerning the patient-matched control groups.

<p>Bla: Blastomere; PB: polar body; TE: trophectoderm cells;</p>*<p>Chromosomes involved in the matching patient's rearrangement were excluded from the assessed chromosomes.</p>**<p>Abnormalities affecting chromosomes involved in the matching patient's rearrangement were excluded.</p